Project: GT-002 for the treatment of schizophrenia.

The aim is to advance a new drug candidate (GT-002) through Phase 1 clinical studies in healthy volunteers for later development of clinical proof of concept in the treatment of schizophrenia. Healthy male volunteers will first be administered GT-002 in a Single Ascending Dose (SAD) study, combined with assessment of food effects on absorption, followed by a Multiple Ascending Dose (MAD) study. Additional single-dose studies will confirm target engagement with PET imaging and EEG analysis.

Acronym GASH02 (Reference Number: 10687)
Duration 01/03/2016 - 01/03/2019
Project Topic Biological Sciences / Technologies
Network Eurostars 2
Call Eurostars Cut-Off 5

Project partner